Inspire Medical Systems, Inc. to Report Third Quarter 2022 Financial Results on November 1, 2022
Inspire Medical Systems (NYSE: INSP) will announce its Q3 2022 financial results on November 1, following the market's close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Inspire Medical Systems (NYSE: INSP) will announce its Q3 2022 financial results on November 1, following the market's close. Management will hold a conference call at 5:00 p.m. ET to discuss these results and recent business developments. Interested parties can register for the call via a provided link and access a live webcast on Inspire's Investor Relations page. Inspire specializes in minimally invasive solutions for obstructive sleep apnea, featuring its FDA-approved neurostimulation therapy.
Positive
- FDA-approved neurostimulation technology for sleep apnea treatment.
- Upcoming Q3 2022 earnings call may indicate financial and operational growth.
Negative
- None.
Details
News Market Reaction – INSP
The recorded move for INSP in the trading session of this news was +4.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2022 after the close of trading on Tuesday, November 1. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.
To access the call, please use the following link: Inspire's Q3 2022 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.
A simultaneous webcast of the call will be accessible via the Investor Relations page of the Inspire’s website at www.inspiresleep.com. For those not planning to ask a question of management, the Company recommends listening via the webcast.
Following the call, a replay will be available on the Company's Investor Relations website approximately two hours after the event and archived on the site for two weeks.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.